Literature DB >> 11035991

Clinical decision making regarding leiomyomata: what we need in the next millenium.

A F Haney1.   

Abstract

Leiomyomata represent the most common gynecologic tumors and are responsible for over 200,000 hysterectomies per year. They are almost invariably benign and represent clonal expansion of individual myometrial cells. They can cause a variety of symptoms including menometrorrhagia, dysmenorrhea, pelvic pain, reproductive failure, and compression of adjacent pelvic viscera, or be totally asymptomatic. Leiomyomata are more common in African-American women and have a non-Mendelian inheritance pattern with up to a 50% recurrence rate after surgical removal. The therapeutic choices depend on the goals of therapy, with hysterectomy most often used for definitive treatment, and myomectomy when preservation of childbearing is desired. Intracavitary and submucous leiomyomata can be removed by hysteroscopic resection. Laparoscopic myomectomy is now technically possible but apparently with an increased risk of uterine rupture during pregnancy. Although gonadotropin-releasing hormone-agonist-induced hypogonadism can reduce the volume of leiomyomata, the severe side effects and prompt recurrences make them useful only for short-term goals such as reversing anemia or shrinking an intracavitary tumor prior to hysteroscopic resection. Nonextirpative approaches such as myolysis and uterine artery embolization are being evaluated, and may provide more options if they prove to be safe and efficacious in long-term follow-up. Ultimately, if the genetic basis for fibroid development and/or the molecular mechanism(s) of myometrial proliferation are understood, additional nonsurgical therapeutic interventions may be forthcoming. Current clinical needs are to a) determine an effective prevention strategy in genetically predisposed individuals; b) slow the growth of leiomyomata; c) identify the mechanisms of infertility; d) improve early detection; e) develop better surgical techniques; f) reduce recurrences after myomectomy; g) develop nonextirpative options; and h) evaluate their long-term results.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11035991     DOI: 10.1289/ehp.00108s5835

Source DB:  PubMed          Journal:  Environ Health Perspect        ISSN: 0091-6765            Impact factor:   9.031


  21 in total

1.  The association between self-reported major life events and the presence of uterine fibroids.

Authors:  Anissa I Vines; Myduc Ta; Denise A Esserman
Journal:  Womens Health Issues       Date:  2010 Jul-Aug

2.  Identification of proteins with different abundance associated with cell migration and proliferation in leiomyoma interstitial fluid by proteomics.

Authors:  Blendi Ura; Federica Scrimin; Cinzia Franchin; Giorgio Arrigoni; Danilo Licastro; Lorenzo Monasta; Giuseppe Ricci
Journal:  Oncol Lett       Date:  2017-03-29       Impact factor: 2.967

3.  A prospective study of hypertension and risk of uterine leiomyomata.

Authors:  Renée Boynton-Jarrett; Janet Rich-Edwards; Susan Malspeis; Stacey A Missmer; Rosalind Wright
Journal:  Am J Epidemiol       Date:  2005-04-01       Impact factor: 4.897

4.  Genitourinary symptoms and their effects on quality of life in women with uterine myomas.

Authors:  Murat Ekin; Huseyin Cengiz; Emine Öztürk; Cihan Kaya; Levent Yasar; Kadir Savan
Journal:  Int Urogynecol J       Date:  2014-01-17       Impact factor: 2.894

5.  Uterine leiomyomata associated with self-reported stress urinary incontinence.

Authors:  Anca D Dragomir; Jane C Schroeder; AnnaMarie Connolly; Larry L Kupper; Deborah S Cousins; Andrew F Olshan; Donna D Baird
Journal:  J Womens Health (Larchmt)       Date:  2010-02       Impact factor: 2.681

6.  Stimulatory and inhibitory effects of genistein on human uterine leiomyoma cell proliferation are influenced by the concentration.

Authors:  A B Moore; L Castro; L Yu; X Zheng; X Di; M I Sifre; G E Kissling; R R Newbold; C D Bortner; D Dixon
Journal:  Hum Reprod       Date:  2007-08-27       Impact factor: 6.918

7.  Massive uterine lipoleiomyoma and leiomyoma in a miniature poodle bitch.

Authors:  Aaron Percival; Ameet Singh; R Alex Zur Linden; Gwyneth Watrous; Steven Patten; Alexander Valverde; Emily Ratsep
Journal:  Can Vet J       Date:  2018-08       Impact factor: 1.008

8.  The expression of selenium-binding protein 1 is decreased in uterine leiomyoma.

Authors:  Peng Zhang; Cunxian Zhang; Xudong Wang; Fang Liu; C James Sung; M Ruhul Quddus; W Dwayne Lawrence
Journal:  Diagn Pathol       Date:  2010-12-09       Impact factor: 2.644

9.  Genome-wide DNA methylation indicates silencing of tumor suppressor genes in uterine leiomyoma.

Authors:  Antonia Navarro; Ping Yin; Diana Monsivais; Simon M Lin; Pan Du; Jian-Jun Wei; Serdar E Bulun
Journal:  PLoS One       Date:  2012-03-13       Impact factor: 3.240

10.  Transvesical enucleation of multiple leiomyoma of bladder and urethra.

Authors:  Alireza Ghadian; Seyyed Yousef Hoseini
Journal:  Nephrourol Mon       Date:  2012-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.